Derma Sciences Announces Date of Its First Quarter 2009 Earnings Release and Conference...

Derma Sciences Announces Date of Its First Quarter 2009 Earnings Release and
Conference Call

PRINCETON, N.J., May 11 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC
Bulletin Board: DSCI), a provider of advanced wound care products, announced
plans to release its first quarter 2009 results before market on Monday, May
18, 2009. The Company will hold a conference call that same day to discuss
the results at 11:00 am EDT. Interested parties should call 800-299-8538
(domestic) or 617-786-2902 (international), with passcode 98098954 to access
the call. You may also access this call via the Internet at:

http://phx.corporate-ir.net/playerlink.zhtml?c=107533&s=wm&e=2182603

For those who are unavailable to listen to the live broadcast, a replay will
be available through June 18, 2009 and can be accessed by dialing 888-286-8010
(domestic), and 617-801-6888 (international). The passcode is 82270316.

About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound care
products. Its key product, MEDIHONEY(R), is sold throughout the world by Derma
Sciences and Comvita New Zealand -- the licensor of the patented honey-based
technology -- and is the leading brand of honey-based dressings for the
management of wounds and burns. The product has been shown to be effective in
a variety of wounds and burns, and was the focus of a positive large-scale
randomized controlled trial on leg ulcers. Derma's recently FDA cleared
BIOGUARD(TM) Barrier Dressing is the Company's latest new product entrant into
the $14 billion global wound care market. The barrier technology was licensed
from Quick-Med Technologies, Inc. in Q1 of 2007. Derma also has in development
DSC127, a novel angiotensin analog for accelerated wound healing and scar
reduction. DSC127 was licensed from the University of Southern California in
Q4 of 2007. Patient enrollment for a Phase II study began in Q4 of 2008.
Results from this study are expected to be submitted to the FDA in Q2 of 2010.
For more information about Derma Sciences, Inc., visit
http://www.dermasciences.com.

Contact:

Derma Sciences, Inc.
Edward J. Quilty
Chairman and CEO
equilty@dermasciences.com
(609) 514-4744

Allen & Caron Inc
Rudy Barrio (US Investors)
r.barrio@allencaron.com
(212) 691-8087

Brian Kennedy (Media)
brian@allencaron.com
(212) 691-8087

SOURCE Derma Sciences, Inc.

Edward J. Quilty, Chairman and CEO of Derma Sciences, Inc., +1-609-514-4744,
equilty@dermasciences.com; or US Investors, Rudy Barrio,
r.barrio@allencaron.com, or Media, Brian Kennedy, brian@allencaron.com, both
of Allen & Caron Inc, +1-212-691-8087, for Derma Sciences, Inc.